Li Li1, Alejandro P Ugalde1, Colinda L G J Scheele2, Sebastian M Dieter1, Remco Nagel1, Jin Ma3, Abhijeet Pataskar1, Gozde Korkmaz1, Ran Elkon4, Miao-Ping Chien5, Li You5, Pin-Rui Su5, Onno B Bleijerveld6, Maarten Altelaar6,7, Lyubomir Momchev1, Zohar Manber4, Ruiqi Han1, Pieter C van Breugel1, Rui Lopes1, Peter Ten Dijke3, Jacco van Rheenen2, Reuven Agami8,9. 1. Division of Oncogenomics, The Netherlands Cancer Institute, Plesmanlaan 121, 1066CX, Amsterdam, The Netherlands. 2. Division of Molecular Pathology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands. 3. Department of Molecular Cell Biology, Cancer Genomics Centre Netherlands, Leiden University Medical Center, Leiden, The Netherlands. 4. Department of Human Molecular Genetics and Biochemistry, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel. 5. Department of Molecular Genetics, Erasmus University Medical Center, Rotterdam, The Netherlands. 6. Proteomics Facility, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands. 7. Biomolecular Mass Spectrometry and Proteomics, Bijvt Centre for Biomolecular Research and Utrecht Institute for Pharmaceutical Sciences, University of Utrecht, Padualaan 8, 3584CH, Utrecht, The Netherlands. 8. Division of Oncogenomics, The Netherlands Cancer Institute, Plesmanlaan 121, 1066CX, Amsterdam, The Netherlands. r.agami@nki.nl. 9. Erasmus MC, Rotterdam University, Rotterdam, The Netherlands. r.agami@nki.nl.
Abstract
BACKGROUND: Frequent activation of the co-transcriptional factor YAP is observed in a large number of solid tumors. Activated YAP associates with enhancer loci via TEAD4-DNA-binding protein and stimulates cancer aggressiveness. Although thousands of YAP/TEAD4 binding-sites are annotated, their functional importance is unknown. Here, we aim at further identification of enhancer elements that are required for YAP functions. RESULTS: We first apply genome-wide ChIP profiling of YAP to systematically identify enhancers that are bound by YAP/TEAD4. Next, we implement a genetic approach to uncover functions of YAP/TEAD4-associated enhancers, demonstrate its robustness, and use it to reveal a network of enhancers required for YAP-mediated proliferation. We focus on EnhancerTRAM2, as its target gene TRAM2 shows the strongest expression-correlation with YAP activity in nearly all tumor types. Interestingly, TRAM2 phenocopies the YAP-induced cell proliferation, migration, and invasion phenotypes and correlates with poor patient survival. Mechanistically, we identify FSTL-1 as a major direct client of TRAM2 that is involved in these phenotypes. Thus, TRAM2 is a key novel mediator of YAP-induced oncogenic proliferation and cellular invasiveness. CONCLUSIONS: YAP is a transcription co-factor that binds to thousands of enhancer loci and stimulates tumor aggressiveness. Using unbiased functional approaches, we dissect YAP enhancer network and characterize TRAM2 as a novel mediator of cellular proliferation, migration, and invasion. Our findings elucidate how YAP induces cancer aggressiveness and may assist diagnosis of cancer metastasis.
BACKGROUND: Frequent activation of the co-transcriptional factor YAP is observed in a large number of solid tumors. Activated YAP associates with enhancer loci via TEAD4-DNA-binding protein and stimulates cancer aggressiveness. Although thousands of YAP/TEAD4 binding-sites are annotated, their functional importance is unknown. Here, we aim at further identification of enhancer elements that are required for YAP functions. RESULTS: We first apply genome-wide ChIP profiling of YAP to systematically identify enhancers that are bound by YAP/TEAD4. Next, we implement a genetic approach to uncover functions of YAP/TEAD4-associated enhancers, demonstrate its robustness, and use it to reveal a network of enhancers required for YAP-mediated proliferation. We focus on EnhancerTRAM2, as its target gene TRAM2 shows the strongest expression-correlation with YAP activity in nearly all tumor types. Interestingly, TRAM2 phenocopies the YAP-induced cell proliferation, migration, and invasion phenotypes and correlates with poor patient survival. Mechanistically, we identify FSTL-1 as a major direct client of TRAM2 that is involved in these phenotypes. Thus, TRAM2 is a key novel mediator of YAP-induced oncogenic proliferation and cellular invasiveness. CONCLUSIONS: YAP is a transcription co-factor that binds to thousands of enhancer loci and stimulates tumor aggressiveness. Using unbiased functional approaches, we dissect YAP enhancer network and characterize TRAM2 as a novel mediator of cellular proliferation, migration, and invasion. Our findings elucidate how YAP induces cancer aggressiveness and may assist diagnosis of cancer metastasis.
Authors: T Mizuno; H Murakami; M Fujii; F Ishiguro; I Tanaka; Y Kondo; S Akatsuka; S Toyokuni; K Yokoi; H Osada; Y Sekido Journal: Oncogene Date: 2012-01-30 Impact factor: 9.867
Authors: K Vuoriluoto; H Haugen; S Kiviluoto; J-P Mpindi; J Nevo; C Gjerdrum; C Tiron; J B Lorens; J Ivaska Journal: Oncogene Date: 2010-11-08 Impact factor: 9.867
Authors: Wei Kang; Joanna H M Tong; Anthony W H Chan; Tin-Lap Lee; Raymond W M Lung; Patrick P S Leung; Ken K Y So; Kaichun Wu; Daiming Fan; Jun Yu; Joseph J Y Sung; Ka-Fai To Journal: Clin Cancer Res Date: 2011-02-23 Impact factor: 12.531
Authors: Sebastian M Dieter; Domenica Lovecchio; Abhijeet Pataskar; Martina K Zowada; Pierre-René Körner; Anna Khalizieva; Olaf van Tellingen; Dirk Jäger; Hanno Glimm; Reuven Agami Journal: Oncogene Date: 2022-07-07 Impact factor: 8.756
Authors: Ji-Qing Chen; Lucas A Salas; John K Wiencke; Devin C Koestler; Annette M Molinaro; Angeline S Andrew; John D Seigne; Margaret R Karagas; Karl T Kelsey; Brock C Christensen Journal: Clin Epigenetics Date: 2022-01-21 Impact factor: 6.551